SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056247
Filing Date
2024-05-09
Accepted
2024-05-09 07:02:28
Documents
60
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q lxeo-20240331.htm   iXBRL 10-Q 1904405
2 EX-31.1 lxeo-ex31_1.htm EX-31.1 11741
3 EX-32.1 lxeo-ex32_1.htm EX-32.1 6679
  Complete submission text file 0000950170-24-056247.txt   7342657

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20240331.xsd EX-101.SCH 1236182
63 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20240331_htm.xml XML 1004209
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

IRS No.: 854012572 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41855 | Film No.: 24928482
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)